Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics
Regeneron Pharmaceuticals, Inc. (REGN)
Today's Latest Price: $573.61 USD
Updated Sep 29 4:00pm
Add REGN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
REGN Stock Summary
- REGN has a market capitalization of $60,847,937,976 -- more than approximately 96.83% of US stocks.
- With a year-over-year growth in debt of 211.53%, Regeneron Pharmaceuticals Inc's debt growth rate surpasses 92.78% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Regeneron Pharmaceuticals Inc is reporting a growth rate of 55.02%; that's higher than 83.97% of US stocks.
- Stocks that are quantitatively similar to REGN, based on their financial statements, market capitalization, and price volatility, are LRCX, AMD, SNPS, MU, and CDNS.
- Visit REGN's SEC page to see the company's official filings. To visit the company's web site, go to www.regeneron.com.
REGN Stock Price Chart Technical Analysis Charts
REGN Price/Volume Stats
| Current price | $573.61 | 52-week high | $664.64 |
| Prev. close | $571.92 | 52-week low | $272.02 |
| Day low | $567.92 | Volume | 352,967 |
| Day high | $576.00 | Avg. volume | 1,130,374 |
| 50-day MA | $600.39 | Dividend yield | N/A |
| 200-day MA | $520.34 | Market Cap | 61.03B |
Regeneron Pharmaceuticals, Inc. (REGN) Company Bio
Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.
REGN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $573.61 | $844.58 | 48% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Regeneron Pharmaceuticals Inc. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 53th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for REGN, they are:
- The company's debt burden, as measured by earnings divided by interest payments, is 108.12; that's higher than 96.23% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than just 10.66% of the free cash flow producing stocks we're observing.
- REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 47.49% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 45% |
| 1% | 46% |
| 2% | 48% |
| 3% | 49% |
| 4% | 51% |
| 5% | 52% |
HRC, ENSG, RSCF, CBPO, and ACIU can be thought of as valuation peers to REGN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...